H Lundbeck A/S
Research H Lundbeck A/S (HLUN-B) on Bullrun: market cap DKK 40.57B, P/E 10.4, dividend yield 2.8%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHLUN-B
- ExchangeCO
- CountryDenmark
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyDKK
- Market capDKK 40.57B
- P/E10.4
- Dividend yield2.8%
- Financial periodQ1 2026
- RevenueDKK 7.13B
- Net incomeDKK 1.66B
- Free cash flowDKK 483.00M
- Gross margin81.7%
Valuation Snapshot
latest market cap is DKK 40.57B; P/E is 10.4; dividend yield is 2.8%.
Peer valuation comparison
Latest P/E is 10.35x versus a Healthcare sector median of 24.46x (57.7% below).
Latest dividend yield is 2.78% versus a Healthcare sector median of 2.11% (31.8% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | DKK 24.63B | DKK 3.19B | DKK 4.93B | 82.7% | 3.22 | DKK 3.43B | DKK 11.19B | DKK 24.90B |
| FY2024 | DKK 22.00B | DKK 3.14B | DKK 2.82B | 80.8% | 3.17 | DKK 4.66B | DKK 16.17B | DKK 25.01B |
| FY2023 | DKK 19.91B | DKK 2.29B | DKK 3.80B | 77.5% | 2.31 | DKK 5.01B | DKK 3.71B | DKK 22.05B |
| FY2022 | DKK 18.25B | DKK 1.92B | DKK 3.15B | 78.3% | 1.93 | DKK 3.55B | DKK 5.10B | DKK 20.78B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | DKK 40.57B | 10.4 | 2.7% | 1.15 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1.15 DKK, yield 2.8%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.95 DKK |
| FY2024 | 0.7 DKK |
| FY2023 | 0.58 DKK |
About H Lundbeck A/S
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is H Lundbeck A/S's market cap?
H Lundbeck A/S's market capitalization is DKK 40.57B.
What is H Lundbeck A/S's P/E ratio?
H Lundbeck A/S's price-to-earnings (P/E) ratio is 10.4.
Does H Lundbeck A/S pay a dividend?
H Lundbeck A/S has a dividend yield of 2.8%.
What does H Lundbeck A/S do?
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression.